-
公开(公告)号:US20210107979A1
公开(公告)日:2021-04-15
申请号:US16802822
申请日:2020-02-27
发明人: Yi ZHANG , Thomas John VAN BLARCOM , Siler PANOWSKI , Silvia K. TACHEVA-GRIGOROVA , Barbra Johnson SASU
摘要: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
-
42.
公开(公告)号:US20210106658A1
公开(公告)日:2021-04-15
申请号:US16882598
申请日:2020-05-25
申请人: PFIZER INC.
发明人: KEITH A. JOHNSON , JASON C. ROUSE , PENELOPE JANE SHARPE , MICHAEL SHAMASHKIN , WENDY CAROL PIACENZA , MARY BETH SWITZER , STACEY B. WESTON , Michael Anthony JANKOWSKI
摘要: Compositions are provided comprising recombinant variants of the human clotting Factor Xa. Such compositions include a wide variety of isoforms and post-translational modifications of FXa and are useful for treating subjects in need of hemostasis.
-
公开(公告)号:US20210100903A1
公开(公告)日:2021-04-08
申请号:US17116587
申请日:2020-12-09
申请人: MERCK PATENT GMBH , PFIZER INC.
IPC分类号: A61K39/395 , C07K16/28
摘要: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
-
公开(公告)号:US20210100798A1
公开(公告)日:2021-04-08
申请号:US17090619
申请日:2020-11-05
申请人: Pfizer Inc.
发明人: David James Edmonds , Kevin James Filipski , Kentaro Futatsugi , Michelle Renee Garnsey , Jack Chang Hung Lee , Daniel Jonathan Smaltz
IPC分类号: A61K31/506 , A61K31/4545 , A61K31/155 , A61K31/7048 , A61K31/4985 , A61P3/06 , C07D401/14 , A61K45/06
摘要: Described herein are compounds of Formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
-
公开(公告)号:US20210100796A1
公开(公告)日:2021-04-08
申请号:US17062982
申请日:2020-10-05
申请人: Pfizer Inc.
发明人: David James Edmonds , Kevin James Filipski , Kentaro Futatsugi , Michelle Renee Garnsey , Jack Chang Hung Lee , Daniel Jonathan Smaltz
IPC分类号: A61K31/506 , C07D401/14 , A61K45/06 , A61P3/06 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61K31/4545
摘要: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
-
公开(公告)号:US10947494B2
公开(公告)日:2021-03-16
申请号:US15775172
申请日:2016-11-10
申请人: Pfizer Inc.
发明人: Sunil Gururao Desai , Michael Allen Hanson , Jonathan Patrick Kinross , Daniel R. Lasko , Scott Ellis Lomberk , Jason Arnold Lotvin , Sujata Kaushikbhai Patel-Brown , Weiqiang Sun , Peter Anthony Tomasello
摘要: The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture. In one aspect, the invention relates to a complex culture medium comprising a vegetable hydrolysate, a yeast extract, and a carbon source. In another aspect, the invention relates to a defined media having a total amino acid concentration greater than about 50 mM. A further aspect of the invention relates to the use of fed batch and perfusion fermentation methods for cultivating polysaccharide-producing bacteria.
-
公开(公告)号:US20210069219A1
公开(公告)日:2021-03-11
申请号:US17082102
申请日:2020-10-28
申请人: Pfizer Inc.
发明人: Joseph Walter Strohbach , Tsutomu Akama , David Clive Blakemore , Robert Toms Jacobs , Peter Jones , David Christopher Limburg , Martins Sunday Oderinde , Matthew Alexander Perry , Jacob John Plattner , Rubben Federico Torella , Yasheen Zhou , Thean Yeow Yeoh
IPC分类号: A61K31/69 , A61K31/519 , C07F5/02
摘要: The present invention relates to boron containing compounds of Formula (I) X—Y—Z Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.
-
公开(公告)号:US20210061902A1
公开(公告)日:2021-03-04
申请号:US16925227
申请日:2020-07-09
申请人: Pfizer Inc. , The Regents of the University of California , The Board of Trustees of the Leland Stanford Junior University
发明人: Isaac J. RONDON , Natasha Crellin , Paul Bessette , Eleonora Trotta , Jeffrey A. Bluestone , Lauren K. Ely , Kenan C. Garcia
IPC分类号: C07K16/24
摘要: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
-
公开(公告)号:US10927178B2
公开(公告)日:2021-02-23
申请号:US16535477
申请日:2019-08-08
申请人: PFIZER INC.
IPC分类号: C12N15/09 , C12N5/10 , C07K16/28 , C07K14/715 , A61K39/395 , C07H21/04 , A61K49/00 , A61K47/68 , A61K39/00
摘要: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
-
公开(公告)号:US20210047325A1
公开(公告)日:2021-02-18
申请号:US17034295
申请日:2020-09-28
申请人: Pfizer Inc.
IPC分类号: C07D471/10 , C07D491/20 , C07D519/00 , A61K31/438 , A61K31/519 , A61K45/06 , C07D487/10 , A61K31/435
摘要: The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
-
-
-
-
-
-
-
-
-